Clinical use of indium-111 labeled blood products.
Following the introduction of In-111 oxine as a label for blood cells by McAffee and Thakur in 1976, these procedures have become increasingly important in the practice of nuclear medicine. Of particular interest are studies involving the use of labeled leukocytes for the detection of focal infection. The clinical utility of labeled platelets is less well developed, although the use of platelets to detect the formation of thrombi in blood vessels and on vascular grafts and prostheses is gaining prominence. This report summarizes the techniques presently employed at the University of Minnesota for the labeling of blood products, and their clinical use. Consideration also is given to the desired expertise and cost factors involved in the labeling of leukocytes and platelets.
D000005:Abdomen / Q000000981:diagnostic imaging; D000818:Animals; D001792:Blood Platelets / Q000166:cytology / Q000502:physiology; D002469:Cell Separation / Q000379:methods; D004285:Dogs; D005069:Evaluation Studies as Topic; D006801:Humans; D006912:Hydroxyquinolines; D007204:Indium; D007553:Isotope Labeling / Q000379:methods*; D007700:Kinetics; D007962:Leukocytes / Q000166:cytology / Q000502:physiology; D008171:Lung Diseases / Q000000981:diagnostic imaging; D009942:Organometallic Compounds; D015125:Oxyquinoline / Q000031:analogs & derivatives; D011786:Quality Control; D011868:Radioisotopes; D011877:Radionuclide Imaging; D012187:Retroperitoneal Space
D006912:Hydroxyquinolines; D009942:Organometallic Compounds; D011868:Radioisotopes; D007204:Indium; C032950:indium oxine; D015125:Oxyquinoline